Fragile X Syndrome and Alzheimers Disease: Another Story About APP and β -Amyloid

Author(s): J.S. Malter, B.C. Ray, P.R. Westmark, C.J. Westmark

Journal Name: Current Alzheimer Research

Volume 7 , Issue 3 , 2010

Become EABM
Become Reviewer
Call for Editor


As the mechanisms underlying neuronal development and degeneration become clarified, a number of common effectors and signaling pathways are becoming apparent. Here we describe the identification of Aβ, long considered a pathologic mediator of Alzheimers Disease and Down Syndrome, as similarly over-expressed in the neurodevelopmental disease, Fragile X Syndrome. We also show that mGluR5 inhibitors, currently employed for the treatment of Fragile X, reduce Aβ production in rodent models of Fragile X and AD as well as reduce disease phenotypes including seizures. Thus seemingly disparate neurologic diseases may share a common pathologic instigator and be treatable with a common, currently available class of therapeutics.

Keywords: Metabotropic glutamate receptors (mGluR), Fragile X Syndrome (FXS), amyloid precursor protein (APP), beta-amyloid

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Page: [200 - 206]
Pages: 7
DOI: 10.2174/156720510791050957
Price: $65

Article Metrics

PDF: 7